Skip to main content
en
fr
Search form
Search
Main menu
About us
Our mission
Facts & Figures
Our Strategy
Corporate Governance/ Executive Committee
bioMérieux Worldwide
Our History
Innovation
Institut Mérieux
Responsibility
Our ambition
Health
Planet
Healthcare ecosystem
Employees
Extended Company
RESISTANCE TO ANTIBIOTICS
COVID-19 EXCEPTIONAL DONATIONS
Solutions
Clinical Solutions
Industry Solutions
Product Quality & Safety
Customer Service
Cybersecurity
Resource Center
CLINICAL SOLUTIONS
INDUSTRY SOLUTIONS
Expertise
The importance of diagnostics
Clinical diagnostics
Industrial Microbiological Control
Clinical applications
Infectious diseases
COVID-19
Antimicrobial resistance and Healthcare-associated infections
Cardiovascular Emergencies
Personalized medicine
Industrial applications
Agri-food sector
Biopharma & cosmetics sectors
Our technologies, systems and services
Microbiology
Molecular Biology
Immunoassays
Services
Glossary of Scientific Terms
Education
Antimicrobial Resistance / Antimicrobial Stewardship
Webinars
Educational Materials
External Resources
Sepsis / Bloodstream Infections
Webinars
Educational Tutorials
Educational Materials
External Resources
COVID-19
Webinars
Acute Kidney Injury
Webinars & Symposiums
Educational Materials
External Resources
Cardiac Emergencies
Educational Tutorials
Educational Materials
Educational booklets
Investors
The bioMérieux Share
Publications
Regulated Information
Governance
Shareholder area
UNIVERSAL REGISTRATION DOCUMENT
CORPORATE SOCIAL RESPONSIBILITY
Newsroom
Press Releases
Corporate calendar
Media Center
About bioMérieux
bioMérieux announces the CE marking of the new generation semi-quantitative VIDAS® SARS-COV-2 IgG II serology test
PRESS CONTACTS
Careers
Joining bioMérieux
Corporate culture
Public health mission
International presence
Professional development
Diversity and inclusion
Well-being at work
Compensation and benefits
Job Profiles
R&D
Manufacturing
Supply Chain
Information Systems
Quality
Business
Support Functions
Medical Affairs
HSE
Clinical Affairs and Regulatory Affairs
Contact us
About us
Our mission
Facts & Figures
Our Strategy
Corporate Governance/ Executive Committee
bioMérieux Worldwide
Our History
Innovation
Institut Mérieux
Responsibility
Our ambition
Health
Planet
Healthcare ecosystem
Employees
Extended Company
Solutions
Clinical Solutions
Industry Solutions
Product Quality & Safety
Customer Service
Cybersecurity
Resource Center
Expertise
The importance of diagnostics
Clinical applications
Industrial applications
Our technologies, systems and services
Glossary of Scientific Terms
Education
Antimicrobial Resistance / Antimicrobial Stewardship
Sepsis / Bloodstream Infections
COVID-19
Acute Kidney Injury
Cardiac Emergencies
Educational booklets
Investors
The bioMérieux Share
Publications
Regulated Information
Governance
Shareholder area
Newsroom
Press Releases
Corporate calendar
Media Center
About bioMérieux
Careers
Joining bioMérieux
Job Profiles
Contact us
Investor Relations
Press Contacts
en
fr
Search form
Search
bioMérieux Corporate Website |
Pioneering diagnostics
Philanthropy
Covid-19 Exceptional Donations: discover the actions supported by bioMérieux to help people made vulnerable by the health crisis.
Gender Equality
bioMérieux is part of the Top 100 of Equileap's global ranking!
COVID-19
FAQ on our commitment to fight against COVID-19
Investors
Discover our investors-dedicated section
Press releases
May 07, 2021
bioMérieux announces the CE marking of the new generation semi-qua...
April 30, 2021
bioMérieux announces CE-marking of the new MALDI-TOF mass spectrom...
April 27, 2021
bioMérieux – First-Quarter 2021 Business Review
April 07, 2021
bioMérieux announces the CE marking of 3 dengue immunoassays on VI...
